Effects of high-fat diet and fructose-rich diet on obesity, dyslipidemia and hyperglycemia in the WBN/Kob-<i>Lepr^fa</i> rat, a new model of type 2 diabetes mellitus

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are occurring at epidemic-like rates, and these epidemics appear to have emerged largely from changes in daily diet. In the present study, we compared effects of high-fat diet (HFD) and fructose-rich diet (FRD) in WBN/Kob-Leprfa (WBKDF) rats that spontaneously develop obesity, dyslipidemia and T2DM. After a 4-week feeding of each diet, WBKDF-HFD and WBKDF-FRD rats exhibited aggravated obesity and dyslipidemia compared with WBKDF rats fed standard diet (STD). In contrast, hyperglycemia developed in WBKDF-STD rats was significantly inhibited in WBKDF-FRD rats, but not in WBKDF-HFD rats. The present study demonstrated that the 4-week feeding of HFD and FRD caused diet-induced obesity with a distinct phenotype in the glucose metabolism in WBKDF rats.

Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet

“…Pre‐diabetic WBKDF rats fed a standard diet are obese and this may be associated with hyperphagia due to the fa gene . HFD causes diet‐induced obesity in humans and various experimental animals, including WBKDF rats . Accordingly, the obesity that develops in WBKDF‐HFD rats includes genetic obesity and HFD‐induced obesity components.…”

“…The availability of useful animal models reflecting human obesity syndrome is crucial in the search for new pharmacological compounds to treat obesity. In the previous study, we developed rat models of human MS by feeding HFD or a fructose‐rich diet (FRD) to WBKDF rats, and showed that WBKDF‐HFD rats developed obesity, dyslipidemia, and especially severe hyperglycemia compared to WBKDF‐FRD rats . To obtain further information on the model as a potential experimental animal model of severe MS, we performed a pharmacological investigation on the effects of liraglutide, which is a currently approved GLP‐1 agonist for the treatment of T2DM and obesity .…”

“…The current study showed that WBKDF‐HFD rats share a number of important characteristics, especially marked hyperglycemia, compared with WBKDF‐FRD rats, with human MS patients. In addition, this study clearly showed a strong response of WBKDF‐HFD rats to liraglutide, which is used clinically to treat human MS. Our data highlight the usefulness of WBKDF‐HFD rats for a screening of compounds affecting food intake, body weight, glucose homeostasis, dyslipidemia and NAFLD.…”

“…To develop an animal model mimicking the structural and functional features of MS in people with T2DM, HFD feeding is commonly used in experimental animals. Our previous study demonstrated that 4‐week feeding of a HFD caused diet‐induced obesity and aggravated hyperlipidemia and hyperglycemia in WBKDF rats …”

Sporidiobolus pararoseuswall-broken powder ameliorates oxidative stress in diabetic nephropathy in type-2 diabetic mice by activating the Nrf2/ARE pathway

“…1 It is concerning that type 2 diabetes (T2DM) is caused by obesity; cases of T2DM are rapidly increasing and may result in a worldwide epidemic. 2,3 Furthermore, hyperglycemia in diabetes ultimately leads to long-term damage and complications, including heart and cardiovascular diseases, tissue damage to the liver and pancreas, diabetic ophthalmopathy and chronic kidney disease. 4 Previous studies demonstrated that the morphological characteristics of diabetic nephropathy (DN) include glomerular hypertrophy, tubular atrophy of the basement, mesangial expansion, membrane thickening, interstitial brosis and arteriolar thickening.…”